NCT00154349View on ClinicalTrials.gov

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

February 28, 2007

Study Completion Date

February 28, 2007

Conditions
Philadelphia Chromosome Positive Acute Lymphocytic Leukemia
Interventions
DRUG

Imatinib Mesylate

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY